Michael Botsko
Overview
Explore the profile of Michael Botsko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parsons J, Lelutiu-Weinberger C, Botsko M, Golub S
J Consult Clin Psychol
. 2013 Dec;
82(1):9-18.
PMID: 24364800
Objective: Young gay and bisexual men (YGBM) are disproportionally at risk of HIV infection due to sexual risk behaviors, which are often exacerbated by recreational drug use. However, there have...
2.
Parsons J, Kowalczyk W, Botsko M, Tomassilli J, Golub S
AIDS Behav
. 2013 Apr;
17(4):1478-87.
PMID: 23553345
Methamphetamine use is associated with HIV infection, especially among gay and bisexual men. Methamphetamine use contributes to disease progression both directly, by increasing viral load and damaging the immune system,...
3.
Parsons J, Lelutiu-Weinberger C, Botsko M, Golub S
AIDS Behav
. 2012 May;
17(4):1465-77.
PMID: 22614745
As HIV infection rates remain high among young gay and bisexual men, investigations into determinants of sexual risk are paramount. This study examined independent and interactive effects of substance use,...
4.
Lum P, Little S, Botsko M, Hersh D, Thawley R, Egan J, et al.
J Acquir Immune Defic Syndr
. 2011 Feb;
56 Suppl 1:S91-7.
PMID: 21317601
Background: Pain syndromes are common in HIV-infected patients, who also are commonly affected by opioid-use disorders. Although opioids can treat pain, prescribers must consider the consequences of iatrogenic or missed...
5.
Korthuis P, Fiellin D, Fu R, Lum P, Altice F, Sohler N, et al.
J Acquir Immune Defic Syndr
. 2011 Feb;
56 Suppl 1:S83-90.
PMID: 21317600
Background: Opioid-dependent HIV-infected patients are less likely to receive HIV quality of care indicators (QIs) compared with nondependent patients. Buprenorphine/naloxone maintenance therapy (bup/nx) could affect the quality of HIV care...
6.
Schackman B, Leff J, Botsko M, Fiellin D, Altice F, Korthuis P, et al.
J Acquir Immune Defic Syndr
. 2011 Feb;
56 Suppl 1:S76-82.
PMID: 21317599
Background: Implementing integrated HIV and buprenorphine/naloxone treatment requires cost estimates to plan and obtain funding. Methods: We identified costs incurred at HIV clinical sites participating in a cross-site evaluation of...
7.
Weiss L, Egan J, Botsko M, Netherland J, Fiellin D, Finkelstein R
J Acquir Immune Defic Syndr
. 2011 Feb;
56 Suppl 1:S7-13.
PMID: 21317598
Substance abuse is associated with poor medical and quality-of-life outcomes among HIV-infected individuals. Although drug treatment may reduce these negative consequences, for many patients, options are limited. Buprenorphine/naloxone, an opioid...
8.
Vergara-Rodriguez P, Tozzi M, Botsko M, Nandi V, Altice F, Egan J, et al.
J Acquir Immune Defic Syndr
. 2011 Feb;
56 Suppl 1:S62-7.
PMID: 21317596
Background: The safety of buprenorphine/naloxone (bup/nx) in HIV-infected patients has not been established. Prior reports raise concern about hepatotoxicity and interactions with atazanavir. Methods: We conducted a prospective cohort study...
9.
Sullivan L, Botsko M, Cunningham C, OConnor P, Hersh D, Mitty J, et al.
J Acquir Immune Defic Syndr
. 2011 Feb;
56 Suppl 1:S54-61.
PMID: 21317595
Background: Cocaine use is common in opioid-dependent HIV-infected patients, but its impact on treatment outcomes in these patients receiving buprenorphine/naloxone is not known. Methods: We conducted a prospective study in...
10.
Korthuis P, Tozzi M, Nandi V, Fiellin D, Weiss L, Egan J, et al.
J Acquir Immune Defic Syndr
. 2011 Feb;
56 Suppl 1:S39-45.
PMID: 21317593
Background: Opioid dependence and HIV infection are associated with poor health-related quality of life (HRQOL). Buprenorphine/naloxone (bup/nx) provided in HIV care settings may improve HRQOL. Methods: We surveyed 289 HIV-infected...